Oscient (AWE-see-int) Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products in the United States: ANTARA® (fenofibrate) capsules, a cardiovascular product and FACTIVE® (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity.
- 6-11-09 - Oscient Pharmaceuticals Discontinues Sales Force Promotion for ANTARA and FACTIVE
- 5-15-09 - Oscient Pharmaceuticals Files Form 12b-25 Notification of Late Filing for Form 10-Q for Quarterly Period Ended March 31, 2009
- 3-25-09 - Oscient Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results
- 3-24-09 - NASDAQ Extends Temporary Suspension of Bid Price and Market Value of Publicly Held Shares Requirements; Oscient Compliance Period Extended to October 6, 2009
- 2-11-09 - Oscient Pharmaceuticals Restructures Commercial Organization
- 1-29-09 - Oscient Pharmaceuticals Extends Maturity of its Privately Placed 5% Convertible Promissory Notes
- See All News Releases
